BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa [Reuters]
InflaRx N.V. (IFRX)
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Company Research
Source: Reuters
BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa | Reuters Reuters Staff 1 Min Read Jan 9 (Reuters) - Inflarx Nv: * INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA * INFLARX NV - ?INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018? Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa Jan 9 (Reuters) - Inflarx Nv: * INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA * INFLARX NV - ?INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018? Source text for Eikon: Further company coverage:
Show less
Read more
Impact Snapshot
Event Time:
IFRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IFRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
News
- Global Sepsis Therapeutics Strategic Research Report 2024: Market to Reach $7.1 Billion by 2030 - Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth [Yahoo! Finance]Yahoo! Finance
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans [Yahoo! Finance]Yahoo! Finance
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansGlobeNewswire
IFRX
Earnings
- 8/10/23 - Beat
IFRX
Analyst Actions
- 3/22/24 - HC Wainwright
IFRX
Sec Filings
- 4/4/24 - Form 6-K
- 3/21/24 - Form 6-K
- 3/21/24 - Form 20-F
- IFRX's page on the SEC website